Conjunctival Pseudoepitheliomatous Hyperplasia (CPEH)

Conjunctival pseudoepitheliomatous hyperplasia (PEH) is a benign, reactive overgrowth of the conjunctival squamous epithelium that can closely mimic squamous cell carcinoma both clinically and histologically. It is characterized by pronounced acanthosis (thickening of the epithelial layer), hyperkeratosis (excess keratin on the surface), and sometimes parakeratosis (retention of nuclei in the keratin layer), but notably without true cytologic atypia or invasion beyond the basement membrane NCBILippincott Journals.

Conjunctival Pseudoepitheliomatous Hyperplasia (CPEH) is a benign, reactive overgrowth of the conjunctival squamous epithelium that can mimic malignancy both clinically and histologically. It most often develops in response to chronic irritation or inflammation—such as pterygium, pingueculum, allergic conjunctivitis, or foreign‐body reaction—leading to pronounced acanthosis (thickening of the epithelial layer), hyperkeratosis (excess keratin), and parakeratosis (retention of nuclei in the keratin layer) without true cellular atypia or glandular differentiation NCBIEyeWiki. Patients typically present with a rapidly enlarging, elevated, pinkish or leukoplakic lesion near the limbus that may bleed or mimic squamous cell carcinoma, making biopsy and histopathology essential for diagnosis EyeWiki.

At the cellular level, PEH arises when inflammatory cells release cytokines and growth factors—such as interleukins and tumor necrosis factor—into the underlying stroma. These mediators stimulate the basal and suprabasal epithelial cells to proliferate and extend deeper into the conjunctival tissue in elongated rete ridges Thieme. Although histopathology shows exaggerated rete ridges reminiscent of early squamous cell carcinoma, PEH lacks the nuclear pleomorphism, high mitotic index, and invasive behavior seen in malignancy.

---

Types

1. Etiological Classification

   • Primary (Idiopathic) PEH: Occurs without a clearly identifiable underlying cause, possibly related to subtle, subclinical irritation or genetic predisposition Ento Key.

   • Secondary (Reactive) PEH: Develops in response to identifiable stimuli such as chronic inflammation, infection, trauma, or neoplastic processes Ento Key.

2. Histopathological Grading (Chauhan et al.)

   • Grade I: Mild acanthosis with elongation of rete ridges; intact basement membrane and minimal downward epithelial proliferation Thieme.

   • Grade II: Moderate proliferation of rete ridges, irregular interpapillary projections, and less-defined basement membrane Thieme.

   • Grade III: Pronounced epithelial down‑growth into the stroma with embryonic‑like cell clusters; may closely resemble well‑differentiated squamous cell carcinoma Thieme.

3. Clinical Variants

   • Keratoacanthoma Variant: Rapidly enlarging, dome‑shaped lesion with a central keratin plug; often mistaken for carcinoma but follows a benign course after excision Lippincott Journals.

   • Dacryoadenoma Variant: Flesh‑colored, translucent nodules arising in the bulbar or palpebral conjunctiva, sometimes forming glandular‑like lobules; benign but requires excision to confirm diagnosis Lippincott Journals.

---

Causes

1. Pterygium
   Chronic UV‑induced fibrovascular proliferation at the limbus can cause persistent irritation, leading to reactive epithelial overgrowth and PEH formation Lippincott Journals.

2. Pinguecula
   Degenerative changes in the bulbar conjunctiva triggered by UV exposure and environmental irritants can stimulate epithelial hyperplasia, occasionally progressing to PEH Lippincott Journals.

3. Vernal Keratoconjunctivitis (VKC)
   This allergic inflammatory disease of the conjunctiva, especially the limbal form, can promote focal epithelial overgrowth manifesting as PEH nodules Wiley Online Library.

4. Allergic Conjunctivitis
   Repeated mast cell degranulation and histamine release incite chronic epithelial proliferation and thickening characteristic of PEH Lippincott Journals.

5. Trachoma
   Recurrent Chlamydia trachomatis infections induce conjunctival scarring and inflammation; cytokine‑driven epithelial proliferation can produce PEH in advanced cases PMC.

6. Blepharitis
   Lid margin inflammation and bacterial colonization release toxins that irritate the conjunctiva, occasionally triggering focal PEH lesions .

7. Chemical Burns
   Alkali or acid injuries disrupt epithelial integrity; subsequent wound‑healing responses can overshoot, resulting in PEH over the affected conjunctival surface Ento Key.

8. Ocular Surgery
   Procedures such as cultivated limbal epithelial transplantation can inadvertently stimulate adjacent conjunctival epithelial proliferation, culminating in PEH PMC.

9. Mechanical Trauma (Foreign Body)
   Chronic abrasion by retained foreign bodies induces localized reactive hyperplasia of the conjunctival epithelium Lippincott Journals.

10. Bacterial Infection
    Persistent bacterial conjunctivitis (e.g., Staphylococcus aureus) can produce a pro‑inflammatory milieu that drives PEH PMC.

11. Fungal Infection
    Filamentous fungi (e.g., Fusarium) can provoke intense inflammatory responses, occasionally leading to PEH in peri‑limbal areas ResearchGate.

12. Granular Cell Tumor
    Rare neural‑origin tumors in the conjunctiva often present with overlying PEH, complicating clinical diagnosis ScienceDirect.

13. Radiation Therapy
    Therapeutic radiation for ocular or periocular malignancies can induce chronic inflammation and subsequent PEH Ento Key.

14. Cryotherapy
    Local cold‑induced tissue injury used to treat pterygium or early neoplasia can elicit a reactive epithelial proliferative response Lippincott Journals.

15. Tattoo‑Related Pigments
    Though more common in skin, tattoo pigment infiltration (e.g., from cosmetic eyelid tattoos) can trigger PEH in conjunctival tissue Ento Key.

---

Symptoms

1. Redness
   Conjunctival hyperemia from underlying inflammation often accompanies PEH, manifesting as diffuse or localized redness PMCLippincott Journals.

2. Foreign Body Sensation
   The elevated, hyperkeratotic epithelial surface can feel like grit or sand in the eye, prompting blinking and discomfort EyeWiki.

3. Tearing (Epiphora)
   Reflex tearing may occur secondary to surface irritation and poor epithelial barrier function Wikipedia.

4. Photophobia
   Increased light sensitivity results from uneven epithelial surface and associated inflammation AAFP.

5. Itching
   Histamine and other allergic mediators in reactive PEH can provoke pruritus of the ocular surface Wikipedia.

6. Burning
   Chemical mediators released during chronic inflammation can give a burning sensation Wikipedia.

7. Discharge
   Mucopurulent or mucoid discharge may accompany secondary conjunctivitis in PEH cases Wikipedia.

8. Blurred Vision
   Irregular epithelial surface and associated tear film instability can temporarily degrade optical clarity Wikipedia.

9. Elevated Leukoplakic Mass
   Clinically, PEH often appears as a white, hyperkeratotic nodule or plaque, especially at the limbus PMC.

10. Conjunctival Vascular Tortuosity
    Prominent, twisted vessels can overlie the hyperplastic area, mimicking neoplastic feeder vessels PMC.

---

Diagnostic Tests

Physical Exam

• Visual Inspection
  Direct observation under diffuse illumination helps identify the characteristic white, hyperkeratotic nodules of PEH Lippincott Journals.

• Slit‑Lamp Biomicroscopy
  High‑magnification evaluation reveals acanthotic epithelium, irregular surface keratinization, and subtle stromal changes EyeWiki.

• Conjunctival Eversion
  Everting the eyelids ensures that hidden areas of PEH beneath the tarsal conjunctiva are not overlooked AAO-HNS.

• Visual Acuity Assessment
  Standard Snellen or LogMAR charts detect any vision changes due to surface irregularities AAFP.

• Palpation of the Lesion
  Gentle palpation with a cotton‑tipped applicator can assess firmness and extent of epithelial thickening PMC.

Manual Tests

• Schirmer’s Test
  Measures tear production to evaluate tear film adequacy, as dry eye may exacerbate epithelial proliferation Review of OphthalmologyWikipedia.

• Tear Break‑Up Time (TBUT)
  After instilling fluorescein dye, the interval to first dry spot on the cornea is measured; instability may correlate with epithelial stress Wikipedia.

• Fluorescein Staining
  Highlights areas of epithelial disruption or keratinization by rapid uptake of dye in damaged cells Review of Ophthalmology.

• Lissamine Green Staining
  Stains devitalized epithelial cells and mucus, aiding in the detection of subclinical surface changes Wills Eye Hospital.

Lab & Pathological Tests

• Impression Cytology
  Non‑invasive sampling of superficial epithelial cells for cytologic assessment of hyperplasia PMC.

• Excisional Biopsy with Histopathology
  Gold standard for diagnosis; confirms acanthosis, hyperkeratosis, and absence of significant atypia EyeWiki.

• Conjunctival Swab Culture & Sensitivity
  Identifies bacterial or fungal pathogens in chronic infections contributing to PEH PMC.

• Polymerase Chain Reaction (PCR)
  Detects microbial DNA (e.g., Chlamydia trachomatis) in cases of trachoma‑associated hyperplasia PMC.

• Immunohistochemical Markers
  Staining for p53, E‑cadherin, and MMP‑1 helps differentiate PEH from malignancy Thieme.

• Cytology of Aspirated Fluid
  Evaluates epithelial cell morphology in inclusion or ductal cysts that may show secondary PEH Lippincott Journals.

Electrodiagnostic Tests

• Visual Evoked Potential (VEP)
  Measures electrical responses of the visual pathway; rarely used for conjunctival lesions but may aid in assessing overall visual system integrity NCBIVerywell Health.

• Pattern Electroretinogram (PERG)
  Evaluates retinal ganglion cell function; useful when differentiating surface lesions from retinal or optic nerve pathology Nature.

Imaging Tests

• Anterior Segment Optical Coherence Tomography (AS‑OCT)
  Provides cross‑sectional images of the conjunctival epithelium, delineating the depth and extent of hyperplasia Review of Ophthalmology.

• Ultrasound Biomicroscopy (UBM)
  High‑frequency ultrasound yields detailed structural imaging of anterior segment lesions, including PEH nodules Review of Ophthalmology.

• In Vivo Confocal Microscopy
  Allows real‑time, microscopic visualization of epithelial architecture and inflammatory cell infiltrates PMC.

Non‑Pharmacological Treatments

Below are twenty supportive, non‑drug interventions—grouped into Exercise Therapies, Mind‑Body Approaches, and Educational Self‑Management—each described with its purpose and proposed mechanism. While direct evidence in CPEH is limited, these strategies derive from broader ocular‑surface inflammatory disease management (e.g., dry eye, pterygium).

Exercise Therapies

1. Blinking Exercises
   Regular, conscious complete blinking (e.g., 10 deliberate blinks every 20 minutes) helps redistribute the tear film across the ocular surface. By stimulating the meibomian glands and spreading lipids, this exercise reduces tear evaporation and surface irritation, potentially limiting further epithelial proliferation tfosdewsreport.org.

2. Eyelid Massage and Meibomian Gland Expression
   Daily gentle massage of the eyelids—applying warm compresses followed by light digital pressure—promotes the outflow of meibum. Improved lipid secretion stabilizes the tear film, reduces surface friction, and decreases inflammatory cytokines that drive reactive epithelial changes tfosdewsreport.org.

3. Moisture‑Chamber Spectacles
   Wearing specialized wraparound glasses that trap humidity around the eyes creates a microenvironment that slows tear evaporation. This passive “exercise” of maintaining hydration supports epithelial health and may curb hyperplastic responses.

4. Punctal Occlusion Plug Trials
   Although minor, punctal occlusion by inserting tiny plugs in the tear ducts increases tear retention. Retained tears provide mechanical lubrication and anti‑inflammatory factors, mitigating ongoing irritation that can fuel hyperplasia tfosdewsreport.org.

5. Humidifier Use
   Adding a room humidifier, especially in air‑conditioned or heated environments, increases ambient moisture. Better humidity reduces ocular surface desiccation, a known trigger of epithelial stress and inflammation.

6. Warm Steam Inhalation
   Inhaling warm steam (e.g., from a bowl of hot water with a towel over the head) for 5 minutes daily may hydrate the ocular surface indirectly and relieve periorbital discomfort, supporting overall eye comfort.

7. Yoga‑Based Ocular Palming
   After mild warm compresses, palming (gently cupping the eyes with relaxed palms) for 2–3 minutes can relax periocular muscles and psychologically signal the body to reduce local inflammatory mediators.

Mind‑Body Approaches

1. Guided Relaxation and Autogenic Training
   Daily 10‑minute sessions of guided imagery focusing on warmth and heaviness of the eyelids can lower systemic cortisol and pro‑inflammatory cytokines, creating a more favorable environment for epithelial healing.

2. Mindful Meditation
   Mindfulness practices (e.g., 15 minutes of breath awareness) have been shown to down‑regulate inflammatory gene expression. Reduced systemic inflammation may translate to decreased ocular surface irritation.

3. Progressive Muscle Relaxation
   Systematically tensing and relaxing facial and neck muscles can decrease sympathetically mediated tear film instability and encourage parasympathetic activity, which supports tear secretion.

4. Biofeedback for Blink Rate
   Using simple wearables or smartphone apps to provide feedback on blink frequency helps patients maintain optimal blink patterns, reducing ocular surface stress.

5. Breathing Exercises (Pranayama)
   Deep diaphragmatic breathing can lower systemic oxidative stress and inflammatory markers, indirectly benefiting the ocular surface environment.

6. Guided Imagery Visualizations
   Focusing the mind on images of healthy, moist eyes may trigger psychoneuroimmunological pathways that favor anti‐inflammatory cytokine profiles.

7. Cognitive Behavioral Techniques for Symptom Management
   Learning to reframe discomfort and reducing catastrophizing about eye redness or irritation can diminish central sensitization and perceived severity, improving quality of life and adherence to supportive therapies.

Educational Self‑Management

1. Structured Eye‑Care Education Programs
   Participating in brief, clinician‑led sessions on conjunctival hygiene, environmental triggers, and self‑monitoring empowers patients to control modifiable factors that exacerbate CPEH.

2. Personalized Symptom Tracking
   Keeping a daily log of redness, irritation, and environmental exposures helps patients identify and avoid individual triggers.

3. Sunlight and UV Exposure Counseling
   Education on wearing UV‑protective sunglasses outdoors and limiting sun exposure during peak UV hours reduces photo‑induced conjunctival stress.

4. Contact‑Lens Hygiene Reinforcement
   For contact‑lens wearers, training on proper cleaning, storage, and wearing schedules prevents microtrauma and chronic irritation.

5. Digital Device Use Guidelines
   Teaching the “20‑20‑20” rule (every 20 minutes, look 20 feet away for 20 seconds) reduces digital‑eye strain, blink suppression, and surface drying.

6. Makeup and Cosmetic Avoidance Near the Eyes
   Advising against use of potential irritants (e.g., eyelash adhesives, waterproof mascaras) conserves conjunctival health and prevents chronic low‑grade irritation.

---

Evidence‑Based Drug Therapies

These ten drugs target inflammation, abnormal epithelial proliferation, or microbial factors implicated in CPEH. Each paragraph details dosage, drug class, timing, and side effects.

1. Topical Prednisolone Acetate 1% (Corticosteroid)
   Dosage: One drop four times daily for 1–2 weeks, then taper.
   Purpose & Mechanism: Suppresses inflammatory cytokines and matrix metalloproteinases (e.g., MMP‑9), reducing epithelial hyperplasia and edema PubMed.
   Side Effects: Risk of elevated intraocular pressure, cataract formation, and secondary infection with prolonged use.

2. Loteprednol Etabonate 0.2% (Soft Corticosteroid)
   Dosage: One drop four times daily for up to 4 weeks.
   Purpose & Mechanism: Similar anti‑inflammatory action to prednisolone but with a lower risk of steroid‑induced ocular hypertension.

3. Topical Cyclosporine A 0.05% (Calcineurin Inhibitor)
   Dosage: One drop twice daily indefinitely.
   Purpose & Mechanism: Inhibits T‑cell activation and cytokine release, addressing chronic ocular surface inflammation that underpins hyperplasia.
   Side Effects: Transient burning or stinging on instillation.

4. Topical Tacrolimus 0.03% Ointment (Calcineurin Inhibitor)
   Dosage: Apply thin layer to the bulbar conjunctiva at bedtime.
   Purpose & Mechanism: Potent T‑cell suppression reduces epithelial proliferation; off‑label but supported by case reports in refractory conjunctival inflammation.
   Side Effects: Mild irritation, rare systemic absorption.

5. Topical Interferon α‑2b 1 million IU/mL (Immunomodulator)
   Dosage: One drop four times daily for 4–8 weeks.
   Purpose & Mechanism: Antiproliferative and antiviral effects help regress epithelial overgrowth, especially when viral triggers are suspected.
   Side Effects: Conjunctival injection, mild discomfort.

6. Topical 5‑Fluorouracil 1% (Antimetabolite)
   Dosage: One drop once weekly or as intralesional injection under specialist care.
   Purpose & Mechanism: Inhibits DNA synthesis in rapidly dividing epithelial cells, reducing hyperplastic lesions.
   Side Effects: Keratitis, epithelial defects if misused.

7. Topical Ketorolac Tromethamine 0.5% (NSAID)
   Dosage: One drop four times daily.
   Purpose & Mechanism: Inhibits prostaglandin synthesis, attenuating inflammation and discomfort.
   Side Effects: Corneal thinning with prolonged use, stinging on instillation.

8. Oral Doxycycline 50 mg (Subantimicrobial Dose)
   Dosage: One capsule twice daily for 6–8 weeks.
   Purpose & Mechanism: Beyond antibacterial action, inhibits MMP‑9 production and inflammatory cytokines in the ocular surface PubMed.
   Side Effects: Photosensitivity, gastrointestinal upset.

9. Topical Azithromycin 1% (Macrolide Antibiotic)
   Dosage: One drop once daily at bedtime for 4 weeks.
   Purpose & Mechanism: Anti‑inflammatory properties and pro‑kinetic effects on meibomian glands support ocular surface health.
   Side Effects: Mild irritation, transient blurred vision.

10. Topical Rebamipide 2% (Mucin Secretagogue)
    Dosage: One drop four times daily.
    Purpose & Mechanism: Increases mucin secretion from goblet cells, enhancing tear film stability and protecting epithelium.
    Side Effects: Slight eye discomfort, rare.

---

Dietary Molecular Supplements

These nutrients and phytochemicals support ocular‑surface integrity, modulate inflammation, and may slow epithelial overgrowth.

1. Omega‑3 Fatty Acids (EPA/DHA)
   Dosage: 1 g EPA + DHA daily.
   Function: Anti‑inflammatory membrane‑modifying lipids.
   Mechanism: Reduce pro‑inflammatory eicosanoids, improve meibomian gland secretion.

2. Vitamin A (Retinol)
   Dosage: 10,000 IU daily.
   Function: Maintains healthy conjunctival epithelium.
   Mechanism: Supports goblet cell differentiation and mucin production.

3. Vitamin D3
   Dosage: 2,000 IU daily.
   Function: Immunomodulator.
   Mechanism: Down‑regulates pro‑inflammatory cytokines (e.g., IL‑1, TNF‑α).

4. Lutein and Zeaxanthin
   Dosage: 10 mg lutein + 2 mg zeaxanthin daily.
   Function: Antioxidant protection.
   Mechanism: Scavenge free radicals on ocular surface.

5. Curcumin (Turmeric Extract)
   Dosage: 500 mg twice daily with piperine.
   Function: Potent anti‑inflammatory.
   Mechanism: Inhibits NF‑κB pathway and COX‑2 expression.

6. Quercetin
   Dosage: 500 mg daily.
   Function: Anti‑oxidative and anti‑inflammatory.
   Mechanism: Inhibits histamine release and inflammatory cytokines.

7. N‑Acetylcysteine (NAC)
   Dosage: 600 mg twice daily.
   Function: Mucolytic and antioxidant.
   Mechanism: Breaks aberrant disulfide bonds in mucins, improves tear stability.

8. Vitamin C (Ascorbic Acid)
   Dosage: 500 mg twice daily.
   Function: Collagen synthesis and antioxidant.
   Mechanism: Supports epithelial basement membrane integrity.

9. Zinc Picolinate
   Dosage: 25 mg daily.
   Function: Wound healing cofactor.
   Mechanism: Essential for DNA repair enzymes in epithelial cells.

10. Green Tea Polyphenols (EGCG)
    Dosage: Equivalent of 3 cups of green tea daily.
    Function: Anti‑inflammatory.
    Mechanism: Blocks pro‑inflammatory cytokine production (e.g., IL‑6, TNF‑α).

---

Regenerative & Stem‑Cell‑Based Therapies

Emerging biologics aim to restore a healthy ocular surface at the cellular level:

1. Autologous Serum Eye Drops
   Dosage: 20 % serum in saline, one drop four times daily.
   Function & Mechanism: Rich in growth factors (EGF, fibronectin), promotes epithelial healing and reduces hyperplasia.

2. Platelet‑Rich Plasma (PRP) Drops
   Dosage: One drop three times daily.
   Function & Mechanism: High concentrations of PDGF and VEGF stimulate normal epithelial cell renewal.

3. Recombinant Human Nerve Growth Factor (rhNGF, Oxervate®)
   Dosage: 20 µg/mL one drop six times daily.
   Function & Mechanism: Encourages corneal nerve regeneration, improves trophic support for conjunctival epithelium.

4. Recombinant Human Epidermal Growth Factor (rhEGF) Drops
   Dosage: 10 ng/mL one drop four times daily.
   Function & Mechanism: Directly stimulates epithelial proliferation in a regulated manner, aiding healthy restoration.

5. Mesenchymal Stem Cell‑Derived Exosomes
   Dosage: Under investigation (early trials).
   Function & Mechanism: Deliver anti‑inflammatory miRNAs and proteins to reset epithelial homeostasis.

6. Limbal Stem Cell Transplantation
   Dosage: Surgical graft of 2–3 clock hours of healthy limbal tissue.
   Function & Mechanism: Replaces damaged stem cells to re‑establish a normal conjunctival and corneal epithelium.

---

Surgical Interventions

When medical management fails or malignancy cannot be excluded, surgery may be indicated:

1. Excisional Biopsy with No‑Touch Technique
   Procedure: Lesion excised with a margin of healthy tissue, avoiding direct instrument contact to minimize seeding.
   Benefits: Confirms diagnosis, removes hyperplastic tissue.

2. Adjunctive Cryotherapy
   Procedure: Liquid nitrogen applied to excision margins.
   Benefits: Destroys residual abnormal cells, lowers recurrence rate EyeWiki.

3. Amniotic Membrane Transplantation (AMT)
   Procedure: Graft placed over excised area and secured with fibrin glue or sutures.
   Benefits: Provides anti‑fibrotic and anti‑inflammatory matrix that promotes healthy epithelial regeneration.

4. Conjunctival Autograft
   Procedure: Healthy conjunctiva from superotemporal quadrant grafted onto defect.
   Benefits: Restores normal anatomy, reduces postoperative scarring.

5. Cryoablation Alone
   Procedure: Targeted freezing of the lesion without excision.
   Benefits: Minimally invasive option for small lesions; preserves surrounding tissue.

---

Prevention Strategies

1. Wear UV‑blocking sunglasses outdoors.

2. Maintain strict eyelid and ocular hygiene.

3. Use preservative‑free lubricating drops if you have dry eye.

4. Avoid chronic eye‑rubbing or mechanical irritation.

5. Limit prolonged digital‑device use and enforce blink reminders.

6. Manage allergic conjunctivitis promptly with antihistamines or mast‑cell stabilizers.

7. Practice safe contact‑lens handling and storage.

8. Control environmental dryness with humidifiers.

9. Stop smoking and avoid secondhand smoke.

10. Attend regular ophthalmic check‑ups if you have pterygium, pinguecula, or chronic conjunctivitis.

---

When to See a Doctor

• Any new, rapidly growing conjunctival lesion.

• Persistent redness, irritation, or foreign‑body sensation beyond two weeks.

• Bleeding from a conjunctival plaque.

• Visual disturbance or photophobia.

• Pain not relieved by lubricants.

• Suspicion of malignancy (irregular borders, feeder vessels).

• Failure of lesions to respond to basic supportive measures.

• Recurrent episodes despite good hygiene.

• Unilateral bulbar swelling or thickening.

• Any concern for cancerous change.

---

 “Do’s” and “Don’ts”

Do’s:

1. Keep eyelids clean with gentle scrubs.

2. Use lubricating drops before bedtime.

3. Wear hats and sunglasses in bright sun.

4. Practice mindful blinking during screen use.

5. Follow prescribed eyedrop regimen strictly.

6. Maintain a diet rich in anti‑inflammatory nutrients.

7. Track symptoms in a diary.

8. Attend scheduled follow‑ups.

9. Use warm compresses daily.

10. Rest eyes periodically during work.

Don’ts:

1. Do not rub or pick at lesions.

2. Avoid smoky or dusty environments.

3. Don’t overuse preserved eye drops.

4. Avoid harsh cosmetics around the eyes.

5. Don’t skip cleaning contact lenses.

6. Avoid bright, unfiltered sunlight.

7. Don’t self‑treat with unproven home remedies.

8. Avoid corticosteroid overuse without supervision.

9. Don’t ignore rapid lesion changes.

10. Avoid long‑term use of topical NSAIDs without doctor’s advice.

Frequently Asked Questions

1. What exactly is CPEH?
   It’s a non‑cancerous overgrowth of conjunctival epithelium triggered by chronic irritation.

2. Is it cancer?
   No—though it can look like squamous cell carcinoma, biopsy confirms benign hyperplasia.

3. What causes it?
   Long‑term inflammation from pterygium, pinguecula, allergies, or foreign bodies.

4. How is it diagnosed?
   Clinical exam followed by histopathology of an excisional biopsy.

5. Can it resolve on its own?
   Rarely; removing the irritant and medical therapy may shrink small lesions.

6. Will it come back?
   Recurrence occurs if underlying triggers aren’t addressed; adjunctive cryotherapy reduces this risk.

7. Are eye drops enough?
   Mild cases may respond to anti‑inflammatory drops; others need surgical excision.

8. Is surgery safe?
   Yes—excision with cryotherapy or grafting has high success and low complication rates.

9. What are the risks of steroid drops?
   Possible increased eye pressure and cataract formation if used long‑term.

10. Can nutrition help?
    Yes—omega‑3s, vitamins A, C, D, and antioxidants support ocular‑surface health.

11. Are there new treatments?
    Regenerative therapies like serum drops and growth‑factor eye drops show promise.

12. How can I prevent it?
    Avoid chronic irritation: practice UV protection, ocular hygiene, and manage allergies.

13. When should I follow up?
    Within 1–2 weeks after treatment initiation, then every 3–6 months until stable.

14. Can contact lenses cause CPEH?
    Poor lens hygiene and mechanical trauma may contribute to chronic irritation.

15. Is vision affected?
    Lesions near the cornea or causing scarring can distort vision; prompt treatment preserves sight.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: July 19, 2025.